CN104983737B - Pharmaceutical composition and its application in preparing prevention atherosclerosis, dyslipidemia drug - Google Patents
Pharmaceutical composition and its application in preparing prevention atherosclerosis, dyslipidemia drug Download PDFInfo
- Publication number
- CN104983737B CN104983737B CN201510324417.8A CN201510324417A CN104983737B CN 104983737 B CN104983737 B CN 104983737B CN 201510324417 A CN201510324417 A CN 201510324417A CN 104983737 B CN104983737 B CN 104983737B
- Authority
- CN
- China
- Prior art keywords
- group
- pharmaceutical composition
- ldl
- atherosclerosis
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Purposes the invention discloses a kind of pharmaceutical composition and its in prevention atherosclerosis, dyslipidemia and associated disease drug, wherein being administered in combination flavone compound and sialic acid N n acetylneuraminic acid ns in Atherosclerosis Model apo E knock-out mice.Found by experimental study, the pharmaceutical composition can notable regulating lipid metabolism, reduce blood plasma in triglycerides, cholesterol, malonaldehyde and OxLDL ELISA content, promote the artery model mouse of induction high in fat（Apo E knock-out mice）The activity of superoxide dismutase and lipoprotein esterlysis enzyme, reduction lipid is in the accumulation of lipid of apo E knock-out mice liver and the arch of aorta, the effect of improving aortic disease situation, obtain unexpected concertedness antiatherosclerosis.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and it is athero- to prevent artery in particular to pharmaceutical composition and its in preparation
Application in hardening, dyslipidemia drug.
Background technology
Cranial vascular disease be a kind of high incidence, high disability rate, high case fatality rate disease, main pathologic process is in blood
On the basis of tube wall lesion, blood constituent and（Or）Hemodynamic responses cause ischemic or hemorrhagic disease.Its cause of disease compared with
More, one of them important cause of disease is atherosclerosis, and atherosclerosis can cause artery official jargon to narrow, brain tissue occurs
Blood supply insufficiency, or even can fall off because of patch, it blocks the cerebrovascular and leads to grave consequences.
The major lesions of atherosclerosis are characterized in lipidosis under the inner membrance at the certain positions of artery, and with smooth muscle
The hyperplasia of cell and fibre composition, gradually development form the patch of part, arterial wall also thus thicken and be hardened, inside plaque
The lipid binding of necrosis disintegration and deposition, forms the pathological change of athero- substance.Cholesterol and cholesteryl ester are to constitute athero- spot
The main component of block.When internal cholesterol is excessively high, especially oxidized low-density lipoprotein（OX-LDL）And triglycerides
Increase, then can be swallowed by macrophage, and then be deposited under arterial endothelium, causes subendothelial denaturation, and then blood platelet is caused to exist
Wall of Artery is assembled, if simultaneously with arterial wall damage or cholesterol transport obstacle, easily forms fat spot in endarterium, most
Afterwards, vascular wall swells, forms atheromatous plaque to official jargon inner process.
Lipoprotein lipase（LPL）It is the key enzyme of lipid-metabolism, is synthesized by parenchyma outside liver and be secreted into blood, hydrolysis breast
Rotten particle（chylomicron, CM）And the triglycerides on VLDL（Triglyceride, TG）；LPL shortages can cause CM
Increase with VLDL levels.
Currently, for the essential therapeutic arsenals of atherosclerosis be use angiogenesis inhibitors and fat-reducing medicament, but
It is curative effect is unsatisfactory, and is often accompanied by side effect.Although interventional treatment can make revascularization, restenosis be current
Insurmountable difficult medical problem, especially late result have no clear superiority.
Invention content
The present invention is directed to the above shortcoming, a kind of medical composition and its use is provided, experiments have shown that flavonoids
Object is closed to combine with sialic acid N-acetyl-neuraminate with significant antiatherosclerosis and Bloodlipid-lowering.
The technical solution adopted by the present invention to solve the technical problems is：A kind of pharmaceutical composition, it is main in pharmaceutical composition
It is flavone compound and N-acetyl-neuraminate to want active constituent.
The flavone compound is Quercetin or rutin.
The weight ratio of the flavone compound and N-acetyl-neuraminate is 1:2~4.
Application of the above-mentioned composition in treatment atherosclerosis, dyslipidemia and associated disease drug.
The application of pharmaceutical composition, the daily dosage of each active constituent is Quercetin or rutin in the composition
10-20 mg, N-acetyl-neuraminate 30-40 mg.
The application of pharmaceutical composition, composition are oral preparation.
The dosage form of the application of pharmaceutical composition, the composition is tablet, capsule.
Flavone compound is widely distributed in nature, and is present in the diet of the mankind.Sialic acid is lactation
One kind nine carbon sugar in sugar chain non-reducing end in animal body.Research finds that sialic acid can effectively prevent the particles such as albumen in vivo
Wall deposits in the blood vessels for agglutination and low-density lipoprotein, and has anti-oxidation function；Its shortage is related to accumulation of lipid.
Compared with prior art, composition of medicine of the present invention significantly reduces the total cholesterol of model mice serum
（TC）, triglycerides（TG）, low-density lipoprotein（LDL-C）, malonaldehyde（MDA）And oxidized low-density lipoprotein（OX-
LDL）, promote serum superoxide dismutases（SOD）With lipoprotein esterlysis enzyme（LPL）Activity；It is to be particularly noted that flavones
Class compound combine sialic acid can notable regulating lipid metabolism, reduce serum in TG, TC, LDL-C, MDA content, increase SOD
With LPL activity, the lipid accumulation of lipid subendothelial in the artery model mouse liver and the arch of aorta of induction high in fat is reduced, is improved
Aortic disease situation, the effect of obtaining good concertedness antiatherosclerosis.
Description of the drawings
Fig. 1 show the influence that drug accumulates liver lipids, compared with blank group, #P ＜ 0.05；##P ＜ 0.01；With
Model group is compared, * P ＜ 0.05；* P ＜ 0.01；
Fig. 2 show influence of the drug to arch of aorta accumulation of lipid, compared with blank group, #P ＜ 0.05；##P ＜
0.01；Compared with model group, * P ＜ 0.05；* P ＜ 0.01.
Specific implementation mode
The present invention will be described in detail in the following with reference to the drawings and specific embodiments：
Embodiment 1
The treatment of Quercetin and N-acetyl-neuraminate to Atherosclerosis Model mouse
SPF grades of apo Es knock out（apoE-/-）Mouse, male, 20 ± 2 g of weight.It gives under experimental conditions common
Experimental animal is randomly divided into 5 groups by feed adaptable fed 1 week：Blank group 12, model group 15, Quercetin group 15, N-
N acetylneuraminic acid n group 15 and combination A groups 15.In addition to blank group, high lipid food is given（Formula：Cholesterol 1.25%, courage
Juice salt 0.5%, lard 10%, yolk powder 10%, basal feed 78.25%）；Blank group gives normal diet.After feeding 1 month, respectively
Group gives relative medicine in the case where feed is constant, according to 0.2 mL/kg gavages, and blank group and model group give same volume
Physiological saline, 1 time a day, successive administration 2 months.The test medicine and dosage of each group are as follows：
Blank group：0.2 mL/kg physiological saline；
Model group：0.2 mL/kg physiological saline；
Quercetin group：10 mg/kg Quercetins；
N-acetyl-neuraminate group：The N-acetyl-neuraminate of 40 mg/kg；
Combine A groups：The N-acetyl-neuraminate of+40 mg/kg of 10 mg/kg Quercetins；
During experiment, each group is without animal dead.In fasting 12h after the last administration, blood vessel eye socket is taken using anticoagulant heparin
Venous blood collection 0.8-1.0 mL, yellow Jackets anesthesia are put to death, separated plasma, are saved backup at -80 DEG C；Injection of heart rinses
After remaining blood, heart and liver are won rapidly, and whole aorta of the separation arch of aorta to arteria iliaca communis crotch removes blood
Fat outside pipe and connective tissue carry out microscopy after dyeing.Gained serum sample detects total cholesterol（TC）, triglycerides
（TG）, low-density lipoprotein white level（LDL-C）, hdl level（HDL-C）, superoxide dismutase（SOD）, oxidation
Low-density lipoprotein white level（OX-LDL）, malonaldehyde（MDA）With lipoprotein esterlysis enzyme（LPL）Activity.
The experimental result of influence of the drug to plasma TC, TG, LDL-C and HDL-C is as shown in table 1, and model group is relative to sky
White control group TC, TG and LDL-C significantly rise, and HDL-C is remarkably decreased；Administration group can lower TC, TG and LDL-C, and on
Adjust HDL-C.It is with obvious effects to combine A groups, there is statistical significance relative to model group；N- acetyl ceramide can also significantly reduce
TC and TG, and increase HDL-C.
The experimental result table 2 of influence of the drug to blood plasma LPL activity, MDA, OX-LDL and SOD shows, model group relative to
Blank control group MDA and OX-LDL level significantly rises, and has statistical significance（P ＜ 0.01）, and LPL activity and SOD activity
It is remarkably decreased（P ＜ 0.01）.It is horizontal that administration group, especially pharmaceutical composition A groups can then significantly reduce MDA and OX-LDL（P ＜
0.01）, raise simultaneously LPL activity and SOD activity（P ＜ 0.01）.
Embodiment 2
The treatment of rutin and N-acetyl-neuraminate to Atherosclerosis Model mouse
SPF grades of apo Es knock out（apoE-/-）Mouse, male, 20 ± 2 g of weight.It gives under experimental conditions common
Experimental animal is randomly divided into 5 groups by feed adaptable fed 1 week：Blank group 12, model group 12, rutin group 12, N- second
Acyl neuraminic acid group 12 and combination B groups 12.In addition to blank group, high lipid food is given（Formula：Cholesterol 1.25%, bile
Salt 0.5%, lard 10%, yolk powder 10%, basal feed 78.25%）；Blank group gives normal diet.After feeding 1 month, each group
In the case where feed is constant, relative medicine is given according to 0.2 mL/kg gavages, blank group and model group give the life of same volume
Manage brine, 1 time a day, successive administration 2 months.The test medicine and dosage of each group are as follows：
Blank group：0.2 mL/kg physiological saline；
Model group：0.2 mL/kg physiological saline；
Rutin group：10 mg/kg rutins；
N-acetyl-neuraminate group：The N-acetyl-neuraminate of 30 mg/kg；
Combine B groups：The N-acetyl-neuraminate of+30 mg/kg of 10 mg/kg rutins.
During experiment, each group is without animal dead.In fasting 12h after the last administration, blood vessel eye socket is taken using anticoagulant heparin
Venous blood collection 0.8-1.0 mL, yellow Jackets anesthesia are put to death, separated plasma, are saved backup at -80 DEG C；Injection of heart rinses
After remaining blood, heart and liver are won rapidly, and whole aorta of the separation arch of aorta to arteria iliaca communis crotch removes blood
Fat outside pipe and connective tissue carry out microscopy after dyeing.Gained serum sample detects total cholesterol（TC）, triglycerides
（TG）, low-density lipoprotein white level（LDL-C）, hdl level（HDL-C）, superoxide dismutase（SOD）, oxidation
Low-density lipoprotein white level（OX-LDL）, malonaldehyde（MDA）With lipoprotein esterlysis enzyme（LPL）Activity.
The experimental result of influence of the drug to plasma TC, TG, LDL-C and HDL-C is as shown in Table 3, and model group is relative to sky
White control group TC, TG and LDL-C significantly rise, and HDL-C is remarkably decreased；Administration group can lower TC, TG and LDL-C, and on
Adjust HDL-C.It is with obvious effects to combine B groups, there is statistical significance relative to model group；N- acetyl ceramide can also significantly reduce
TC and TG, and increase HDL-C.
The experimental result of influence of the drug to blood plasma LPL activity, MDA, OX-LDL and SOD is as shown in Table 4, and model group is opposite
It is significantly risen in blank control group MDA and OX-LDL level, there is statistical significance（P ＜ 0.01）, and LPL activity and SOD live
Property is remarkably decreased（P ＜ 0.01）.It is horizontal that administration group, especially pharmaceutical composition B groups can then significantly reduce MDA and OX-LDL（P ＜
0.01）, raise simultaneously LPL activity and SOD activity（P ＜ 0.01）.
Embodiment 3
Quercetin and rutin mixture control Atherosclerosis Model mouse with N-acetyl-neuraminate drug combination
It treats
SPF grades of apo Es knock out（apoE-/-）Mouse, male, 20 ± 2 g of weight.It gives under experimental conditions common
Experimental animal is randomly divided into 5 groups by feed adaptable fed 1 week：Blank group 12, model group 12, mixing Quercetin rutin
Group 12, N-acetyl-neuraminate group 12 and combination C groups 12.In addition to blank group, high lipid food is given（Formula：Courage is solid
Alcohol 1.25%, bile salt 0.5%, lard 10%, yolk powder 10%, basal feed 78.25%）；Blank group gives normal diet.Feed 1
After a month, each group gives relative medicine in the case where feed is constant, according to 0.2 mL/kg gavages, and blank group and model group are given
The physiological saline of same volume is given, 1 time a day, successive administration 2 months.The test medicine and dosage of each group are as follows：
Blank group：0.2 mL/kg physiological saline；
Model group：0.2 mL/kg physiological saline；
Mix Quercetin rutin group：+ 10 mg/kg Quercetins of 10 mg/kg Quercetins；
N-acetyl-neuraminate group：The N-acetyl-neuraminate of 40 mg/kg；
Combine C groups：The N-acetyl-neuraminate of+40 mg/kg of+10 mg/kg rutins of 10 mg/kg Quercetins.
During experiment, each group is without animal dead.In fasting 12h after the last administration, blood vessel eye socket is taken using anticoagulant heparin
Venous blood collection 0.8-1.0 mL, yellow Jackets anesthesia are put to death, separated plasma, are saved backup at -80 DEG C；Injection of heart rinses
After remaining blood, heart and liver are won rapidly, and whole aorta of the separation arch of aorta to arteria iliaca communis crotch removes blood
Fat outside pipe and connective tissue carry out microscopy after dyeing.Gained serum sample detects total cholesterol（TC）, triglycerides
（TG）, low-density lipoprotein white level（LDL-C）, hdl level（HDL-C）, superoxide dismutase（SOD）, oxidation
Low-density lipoprotein white level（OX-LDL）, malonaldehyde（MDA）With lipoprotein esterlysis enzyme（LPL）Activity.
The experimental result of influence of the drug to plasma TC, TG, LDL-C and HDL-C is as shown in Table 5, and model group is relative to sky
White control group TC, TG and LDL-C significantly rise, and HDL-C is remarkably decreased；Administration group can lower TC, TG and LDL-C, and on
Adjust HDL-C.It is with obvious effects to combine C groups, there is statistical significance relative to model group；N- acetyl ceramide can also significantly reduce
TC and TG, and increase HDL-C.
The experimental result of influence of the drug to blood plasma LPL activity, MDA, OX-LDL and SOD is as shown in Table 6, and model group is opposite
It is significantly risen in blank control group MDA and OX-LDL level, there is statistical significance（P ＜ 0.01）, and LPL activity and SOD live
Property is remarkably decreased（P ＜ 0.01）.It is horizontal that administration group, especially pharmaceutical composition C groups can then significantly reduce MDA and OX-LDL（P ＜
0.01）, raise simultaneously LPL activity and SOD activity（P ＜ 0.01）.
Influence of 1 drug of table to plasma TC, TG, LDL-C and HDL-C
| Group | TC (mg/dl) | TG (mg/dl) | LDL-C (mg/dl) | HDL-C (mg/dl) |
| Blank group（n=12） | 457.88±45.86 | 144.91±28.30 | 115.34±11.29 | 100.91±19.67 |
| Model group（n=15） | 845.93±89.02 ## | 195.36±33.41 # | 294.14±20.04 ## | 74.34±9.58 # |
| Quercetin group（n=15） | 709.87±79.73 | 160.28±25.59 | 261.95±47.09 | 87.60±24.44 |
| N-acetyl-neuraminate group（n=15） | 706.23±96.44 * | 64.06±21.82 ** | 254.55±52.29 * | 93.82±19.08 * |
| Combine A groups（n=15） | 563.04±86.17 ** | 56.68±15.04 ** | 198.15±28.8 0** | 116.47±8.30 ** |
Compared with blank group, #P ＜ 0.05；##P ＜ 0.01；
Compared with model group, * P ＜ 0.05；* P ＜ 0.01；
Influence of 2 drug of table to blood plasma LPL activity, MDA, OX-LDL and SOD
Compared with blank group, #P ＜ 0.05；##P ＜ 0.01；
Compared with model group, * P ＜ 0.05；* P ＜ 0.01；
Influence of 3 drug of table to plasma TC, TG, LDL-C and HDL-C
| Group | TC (mg/dl) | TG (mg/dl) | LDL-C (mg/dl) | HDL-C (mg/dl) |
| Blank group（n=12） | 491.05±50.17 | 154.76±32.45 | 121.42±18.68 | 97.55±16.24 |
| Model group（n=12） | 863.51±76.59 ## | 200.05±47.82 # | 289.39±26.74 ## | 69.16±8.37 # |
| Rutin group（n=12） | 720.36±81.07 * | 167.33±19.85 | 256.36±34.82 * | 84.55±17.76 * |
| N-acetyl-neuraminate group（n=12） | 740.34±36.85 * | 84.26±30.12 ** | 243.77±42.61 * | 90.08±11.92 * |
| Combine B groups（n=12） | 607.54±90.26 ** | 73.84±22.73 ** | 211.08±27.84 * | 103.28±11.85 * |
Compared with blank group, #P ＜ 0.05；##P ＜ 0.01；
Compared with model group, * P ＜ 0.05；* P ＜ 0.01；
Influence of 4 drug of table to blood plasma LPL activity, MDA, OX-LDL and SOD
Compared with blank group, #P ＜ 0.05；##P ＜ 0.01；
Compared with model group, * P ＜ 0.05；* P ＜ 0.01；
Influence of 5 drug of table to plasma TC, TG, LDL-C and HDL-C
| Group | TC (mg/dl) | TG (mg/dl) | LDL-C (mg/dl) | HDL-C (mg/dl) |
| Blank group（n=12） | 490.56±65.34 | 167.35±29.95 | 128.09±22.37 | 107.83±21.64 |
| Model group（n=12） | 904.50±91.25 ## | 216.82±40.70 # | 284.98±35.15 ## | 76.41±12.77 # |
| Quercetin and rutin group（n=12） | 785.97±81.22 | 175.04±27.97 | 261.26±29.33 | 89.54±20.81* |
| N-acetyl-neuraminate group（n=12） | 756.38±104.47 * | 89.66±29.74 ** | 244.85±41.78* | 90.39±15.35 * |
| Combine C groups（n=12） | 623.49±69.61 ** | 76.83±30.48 ** | 216.32±38.50 ** | 103.76±16.43 ** |
Compared with blank group, #P ＜ 0.05；##P ＜ 0.01；
Compared with model group, * P ＜ 0.05；* P ＜ 0.01；
Influence of 6 drug of table to blood plasma LPL activity, MDA, OX-LDL and SOD
Compared with blank group, #P ＜ 0.05；##P ＜ 0.01；
Compared with model group, * P ＜ 0.05；* P ＜ 0.01；
Liver organization uses bush uniformly dyeing core, oil red O to contaminate lipid within endothelial cells.Coloration result is in Olympus microscopes
(BX51) it is observed under, object lens 10 × combine IPP image collection processing system gathered datas.Experimental result such as Fig. 1 shows, model group
Relative to blank group lipid in the subendothelial a large amount of accumulations of the arch of aorta, there is statistical significance（P ＜ 0.01）.
The arch of aorta is dyed using oil red O brilliant green, and coloration result is observed under Olympus microscopes (BX51), object lens 10
× combine IPP image collection processing system gathered datas.Experimental result such as Fig. 2 shows, administration group, especially pharmaceutical composition A, B
The subendothelial accumulation of lipid of the arch of aorta can be then significantly reduced with C groups；A, B and C group are combined, there is statistical significance（P ＜ 0.01）.
Certainly, above description is not limitation of the present invention, and the present invention is also not limited to the example above, this technology neck
The variations, modifications, additions or substitutions that the technical staff in domain is made in the essential scope of the present invention should also belong to the present invention's
Protection domain.
Claims (5)
1. a kind of prevention atherosclerosis, the pharmaceutical composition of dyslipidemia, which is characterized in that main in described pharmaceutical composition
It is flavone compound and N-acetyl-neuraminate to want active constituent, and the flavone compound is Quercetin or rutin.
2. prevention atherosclerosis according to claim 1, the pharmaceutical composition of dyslipidemia, which is characterized in that institute
The weight ratio for stating flavone compound and N-acetyl-neuraminate is 1:2-4.
3. application of any compositions of claim 1-2 in preparing prevention atherosclerosis, dyslipidemia drug.
4. the application of pharmaceutical composition according to claim 3, it is characterised in that：Composition is oral preparation.
5. the application of pharmaceutical composition according to claim 4, it is characterised in that：The dosage form of the composition be tablet,
Capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510324417.8A CN104983737B (en) | 2015-06-15 | 2015-06-15 | Pharmaceutical composition and its application in preparing prevention atherosclerosis, dyslipidemia drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510324417.8A CN104983737B (en) | 2015-06-15 | 2015-06-15 | Pharmaceutical composition and its application in preparing prevention atherosclerosis, dyslipidemia drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104983737A CN104983737A (en) | 2015-10-21 |
| CN104983737B true CN104983737B (en) | 2018-07-27 |
Family
ID=54295728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510324417.8A Active CN104983737B (en) | 2015-06-15 | 2015-06-15 | Pharmaceutical composition and its application in preparing prevention atherosclerosis, dyslipidemia drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104983737B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110478357A (en) * | 2019-07-23 | 2019-11-22 | 哈尔滨医科大学 | The application of Nitazoxanide and its cylinder metabolism-ure in anti-obesity, reducing blood lipid, anti-fatty liver and antiatherosclerosis |
| CN113616663A (en) * | 2020-05-08 | 2021-11-09 | 嘉必优生物技术（武汉）股份有限公司 | Use of sialic acid for modulating dyslipidemias caused by abnormal expression of genes responsible for alzheimer's disease |
| CN113171388A (en) * | 2021-04-30 | 2021-07-27 | 广州中医药大学(广州中医药研究院) | Application of total saponins of astragalus or volatile oil of angelica in preparation of reagent for treating diseases related to abnormal protein expression |
| CN114272379A (en) * | 2021-11-26 | 2022-04-05 | 中国科学院生物物理研究所 | Novel small molecule inhibitor targeting Ero1 alpha/PDI electron transfer system |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813797A (en) * | 2004-12-15 | 2006-08-09 | 阿尔贝拉医药控股(通化)有限公司 | Medicinal composition, and its preparing method and use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130058998A1 (en) * | 2011-09-07 | 2013-03-07 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Encapsulated n-acetylmannosamine or n-acetylneuraminic acid to increase sialylation |
-
2015
- 2015-06-15 CN CN201510324417.8A patent/CN104983737B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813797A (en) * | 2004-12-15 | 2006-08-09 | 阿尔贝拉医药控股(通化)有限公司 | Medicinal composition, and its preparing method and use |
Non-Patent Citations (5)
| Title |
|---|
| Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions;John S. Millar等;《Atherosclerosis》;19991231;第145卷;第253-260页 * |
| 乳与胆固醇;吴肖等;《中国乳品工业》;20001031;第28卷(第5期);第34-37页 * |
| 冠心病患者血浆唾液酸含量变化规律及意义;张艳杰等;《中国心血管病研究杂志》;20041031;第2卷(第10期);第835-838页 * |
| 氧化修饰脂蛋白与动脉粥样硬化;田庆印;《中国动脉硬化杂志》;19961231;第4卷(第2期);第149-153页 * |
| 黑果枸杞叶总黄酮抗氧化和降血脂成分测定;吕海英等;《新疆师范大学学报（自然科学版) 》;20120630;第31卷(第2期);第43-48页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104983737A (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101512495B1 (en) | Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction | |
| CN104983737B (en) | Pharmaceutical composition and its application in preparing prevention atherosclerosis, dyslipidemia drug | |
| CN104288345A (en) | A traditional Chinese medicine composition assisting blood lipid reduction and a preparing method thereof | |
| CN105232525A (en) | Hypolipidemic drug combination and application thereof | |
| JP2022538212A (en) | Very long chain fatty acids for disease treatment and alleviation | |
| KR20160064966A (en) | Medical composition and applications thereof used for secondary chemotherapy drugs | |
| CN101284027A (en) | Preparation method of capsules for reducing blood fat | |
| CN102309004A (en) | Functional health food with lowering cholesterol | |
| KR101636345B1 (en) | Composition for preventing or treating thyroid disorders comprising aloe extracts or fraction thereof | |
| CN105920052A (en) | Red yeast rice and euphausia superba oil soft capsule composition having function of reducing blood fat | |
| CN103211761A (en) | Seabuckthorn seed oil oral emulsion with gastric mucosa protective effect and preparation method and use thereof | |
| CN114432337B (en) | Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases | |
| Bazekin et al. | Morphofunctional Assessment of the Glycyrrhizinic Acid Effect on Myocardium of Rats under Adrenaline Loading. | |
| KR20070044198A (en) | Anti-metabolic syndrome treatment with fumaric acid and fumaric acid derivatives | |
| EP2465517A1 (en) | Composition based on extra virgin olive oils | |
| CN102631370B (en) | Composition for preventing or improving hyperlipidemia and supplementing vitamin D | |
| CN106511970B (en) | Application of the rHDL in treatment hypertensive disorder in pregnancy | |
| US20200085774A1 (en) | Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia | |
| CN116549430B (en) | Linoleic acid preparation and application thereof in preparation of acute lung injury treatment drugs | |
| CN107789398A (en) | A kind of pharmaceutical composition of Weight-reducing and lipid-lowering and preparation method thereof | |
| US20240207223A1 (en) | Vitamin c preparation | |
| KR20080094466A (en) | Pharmaceutical composition for treatment of metabolic syndrome | |
| CN117883441A (en) | Pharmaceutical composition containing berberine and taurine and application thereof | |
| WO1999030698A1 (en) | A drug for treating diabetic nephrosis and delaying renal failure | |
| CN103315996B (en) | Pharmaceutical composition used for preventing and controlling atherosclerosis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |